dr. rini on managing the toxicity of pembrolizumab plus axitinib in mrcc
Published 5 years ago • 707 plays • Length 1:03Download video MP4
Download video MP3
Similar videos
-
1:04
dr. rini discusses pembrolizumab plus axitinib in mrcc
-
1:34
dr. rini on pembrolizumab plus axitinib in rcc
-
3:28
dr rini on a biomarker analysis for pembrolizumab/axitinib in advanced rcc
-
1:19
dr. rini on the efficacy of axitinib and pembrolizumab in rcc
-
0:38
dr. rini explains the axitinib integration process
-
1:12
dr. rini describes axitinib's and sorafenib's side effects
-
0:43
dr. rini on the results from his axitinib and sorafenib trial
-
0:43
dr. rini discusses the vegf targeted agent axitinib
-
10:24
the typical prognosis of aggressive renal cell cancer
-
4:58
ben bikman d1 | healthy cells suffering: ir means excessive insulin for healthy cells!
-
10:15
copanlisib and fulvestrant with abemaciclib in her-, er breast cancer
-
2:16
dr. rini on axitinib for treatment of metastatic renal cell carcinoma
-
4:49
pembrolizumab plus axitinib and the future of further-line mrcc treatments
-
2:02
dr. mcgregor on implications of the fda approval of pembrolizumab/axitinib in rcc
-
4:40
pembrolizumab plus axitinib in the second-line and beyond for mrcc
-
0:49
dr. rini describes hypertension as a biomarker in rcc
-
1:38
dr. choueiri on avelumab plus axitinib in mrcc
-
0:43
dr. rini on adjuvant immunotherapy in renal cell carcinoma
-
1:17
dr. vaishampayan on axitinib plus pembrolizumab in advanced rcc
-
1:37
dr. shuch on caveats of avelumab/axitinib combination in rcc
-
1:56
dr. cost on pembrolizumab plus axitinib in patients with rcc
-
1:47
dr. choueiri discusses avelumab/axitinib data in rcc